Prevention of chemotherapy- and radiotherapy-induced emesis

Results of the 2004 Perugia International Antiemetic Consensus Conference

Fausto Roila, Matti Aapro, Enzo Ballatori, Sussanne Borjeson, Rebecca A. Clark-Snow, Albano Del Favero, Lawrence H. Einhorn, Petra Feyer, Richard J. Gralla, Steven M. Grunberg, Jorn Herrstedt, Paul J. Hesketh, Rolf Kaiser, Jim Koeller, Mark G. Kris, Ernesto Maranzano, Alexander Molassiotis, Ian Olver, David Osoba, Bernardo L. Rapoport & 3 others Cynthia Rittenberg, Maurizio Tonato, David Warr

Research output: Contribution to journalArticle

231 Citations (Scopus)

Abstract

Background: In the late 1990s, several professional organizations convened antiemetic guideline groups and published the findings of these expert panels. Each of these documents was based on analyses of the available published trials and provided nearly similar recommendations. Nonetheless, small differences in emetic risk categories and treatment recommendations led to confusion in antiemetics selection. With the emergence of new findings and agents since the guidelines were initially published, many of the oncology professional societies have updated the antiemetic guidelines. Materials and methods: A literature review up to March 2004 was carried out using MEDLINE with evaluation of the evidence by an expert panel composed of 23 oncology professionals in clinical medicine, medical oncology, radiation oncology, oncology nursing, statistics, pharmacy, medical policy and decision making, and pharmacology. The experts represented nine oncology professional societies and came from 11 different countries on four continents. Results: Recommendations on antiemetic regimens to prevent emesis induced by high, moderate, low and minimal risk chemotherapy were suggested as well as management of anticipatory emesis. Furthermore, recommendations for refractory emesis, emesis induced by high-dose chemotherapy and radiotherapy and for antiemetics in children receiving chemotherapy were elaborated. Conclusions: Recommendations about antiemetic prophylaxis in patients receiving treatment with chemo- and radiotherapy have been updated by representatives of nine oncological organizations.

Original languageEnglish (US)
Pages (from-to)20-28
Number of pages9
JournalAnnals of Oncology
Volume17
Issue number1
DOIs
StatePublished - Jan 2006
Externally publishedYes

Fingerprint

Antiemetics
Vomiting
Radiotherapy
Drug Therapy
Guidelines
Oncology Nursing
Emetics
Radiation Oncology
Medical Oncology
Policy Making
Clinical Medicine
MEDLINE
Organizations
Pharmacology
Therapeutics

Keywords

  • 5-HT3-receptor antagonists
  • Acute emesis
  • Aprepitant
  • Delayed emesis
  • Dexamethasone
  • Metoclopramide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Prevention of chemotherapy- and radiotherapy-induced emesis : Results of the 2004 Perugia International Antiemetic Consensus Conference. / Roila, Fausto; Aapro, Matti; Ballatori, Enzo; Borjeson, Sussanne; Clark-Snow, Rebecca A.; Del Favero, Albano; Einhorn, Lawrence H.; Feyer, Petra; Gralla, Richard J.; Grunberg, Steven M.; Herrstedt, Jorn; Hesketh, Paul J.; Kaiser, Rolf; Koeller, Jim; Kris, Mark G.; Maranzano, Ernesto; Molassiotis, Alexander; Olver, Ian; Osoba, David; Rapoport, Bernardo L.; Rittenberg, Cynthia; Tonato, Maurizio; Warr, David.

In: Annals of Oncology, Vol. 17, No. 1, 01.2006, p. 20-28.

Research output: Contribution to journalArticle

Roila, F, Aapro, M, Ballatori, E, Borjeson, S, Clark-Snow, RA, Del Favero, A, Einhorn, LH, Feyer, P, Gralla, RJ, Grunberg, SM, Herrstedt, J, Hesketh, PJ, Kaiser, R, Koeller, J, Kris, MG, Maranzano, E, Molassiotis, A, Olver, I, Osoba, D, Rapoport, BL, Rittenberg, C, Tonato, M & Warr, D 2006, 'Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference', Annals of Oncology, vol. 17, no. 1, pp. 20-28. https://doi.org/10.1093/annonc/mdj078
Roila, Fausto ; Aapro, Matti ; Ballatori, Enzo ; Borjeson, Sussanne ; Clark-Snow, Rebecca A. ; Del Favero, Albano ; Einhorn, Lawrence H. ; Feyer, Petra ; Gralla, Richard J. ; Grunberg, Steven M. ; Herrstedt, Jorn ; Hesketh, Paul J. ; Kaiser, Rolf ; Koeller, Jim ; Kris, Mark G. ; Maranzano, Ernesto ; Molassiotis, Alexander ; Olver, Ian ; Osoba, David ; Rapoport, Bernardo L. ; Rittenberg, Cynthia ; Tonato, Maurizio ; Warr, David. / Prevention of chemotherapy- and radiotherapy-induced emesis : Results of the 2004 Perugia International Antiemetic Consensus Conference. In: Annals of Oncology. 2006 ; Vol. 17, No. 1. pp. 20-28.
@article{9091d726d197457c922f93e2ee037074,
title = "Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference",
abstract = "Background: In the late 1990s, several professional organizations convened antiemetic guideline groups and published the findings of these expert panels. Each of these documents was based on analyses of the available published trials and provided nearly similar recommendations. Nonetheless, small differences in emetic risk categories and treatment recommendations led to confusion in antiemetics selection. With the emergence of new findings and agents since the guidelines were initially published, many of the oncology professional societies have updated the antiemetic guidelines. Materials and methods: A literature review up to March 2004 was carried out using MEDLINE with evaluation of the evidence by an expert panel composed of 23 oncology professionals in clinical medicine, medical oncology, radiation oncology, oncology nursing, statistics, pharmacy, medical policy and decision making, and pharmacology. The experts represented nine oncology professional societies and came from 11 different countries on four continents. Results: Recommendations on antiemetic regimens to prevent emesis induced by high, moderate, low and minimal risk chemotherapy were suggested as well as management of anticipatory emesis. Furthermore, recommendations for refractory emesis, emesis induced by high-dose chemotherapy and radiotherapy and for antiemetics in children receiving chemotherapy were elaborated. Conclusions: Recommendations about antiemetic prophylaxis in patients receiving treatment with chemo- and radiotherapy have been updated by representatives of nine oncological organizations.",
keywords = "5-HT3-receptor antagonists, Acute emesis, Aprepitant, Delayed emesis, Dexamethasone, Metoclopramide",
author = "Fausto Roila and Matti Aapro and Enzo Ballatori and Sussanne Borjeson and Clark-Snow, {Rebecca A.} and {Del Favero}, Albano and Einhorn, {Lawrence H.} and Petra Feyer and Gralla, {Richard J.} and Grunberg, {Steven M.} and Jorn Herrstedt and Hesketh, {Paul J.} and Rolf Kaiser and Jim Koeller and Kris, {Mark G.} and Ernesto Maranzano and Alexander Molassiotis and Ian Olver and David Osoba and Rapoport, {Bernardo L.} and Cynthia Rittenberg and Maurizio Tonato and David Warr",
year = "2006",
month = "1",
doi = "10.1093/annonc/mdj078",
language = "English (US)",
volume = "17",
pages = "20--28",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Prevention of chemotherapy- and radiotherapy-induced emesis

T2 - Results of the 2004 Perugia International Antiemetic Consensus Conference

AU - Roila, Fausto

AU - Aapro, Matti

AU - Ballatori, Enzo

AU - Borjeson, Sussanne

AU - Clark-Snow, Rebecca A.

AU - Del Favero, Albano

AU - Einhorn, Lawrence H.

AU - Feyer, Petra

AU - Gralla, Richard J.

AU - Grunberg, Steven M.

AU - Herrstedt, Jorn

AU - Hesketh, Paul J.

AU - Kaiser, Rolf

AU - Koeller, Jim

AU - Kris, Mark G.

AU - Maranzano, Ernesto

AU - Molassiotis, Alexander

AU - Olver, Ian

AU - Osoba, David

AU - Rapoport, Bernardo L.

AU - Rittenberg, Cynthia

AU - Tonato, Maurizio

AU - Warr, David

PY - 2006/1

Y1 - 2006/1

N2 - Background: In the late 1990s, several professional organizations convened antiemetic guideline groups and published the findings of these expert panels. Each of these documents was based on analyses of the available published trials and provided nearly similar recommendations. Nonetheless, small differences in emetic risk categories and treatment recommendations led to confusion in antiemetics selection. With the emergence of new findings and agents since the guidelines were initially published, many of the oncology professional societies have updated the antiemetic guidelines. Materials and methods: A literature review up to March 2004 was carried out using MEDLINE with evaluation of the evidence by an expert panel composed of 23 oncology professionals in clinical medicine, medical oncology, radiation oncology, oncology nursing, statistics, pharmacy, medical policy and decision making, and pharmacology. The experts represented nine oncology professional societies and came from 11 different countries on four continents. Results: Recommendations on antiemetic regimens to prevent emesis induced by high, moderate, low and minimal risk chemotherapy were suggested as well as management of anticipatory emesis. Furthermore, recommendations for refractory emesis, emesis induced by high-dose chemotherapy and radiotherapy and for antiemetics in children receiving chemotherapy were elaborated. Conclusions: Recommendations about antiemetic prophylaxis in patients receiving treatment with chemo- and radiotherapy have been updated by representatives of nine oncological organizations.

AB - Background: In the late 1990s, several professional organizations convened antiemetic guideline groups and published the findings of these expert panels. Each of these documents was based on analyses of the available published trials and provided nearly similar recommendations. Nonetheless, small differences in emetic risk categories and treatment recommendations led to confusion in antiemetics selection. With the emergence of new findings and agents since the guidelines were initially published, many of the oncology professional societies have updated the antiemetic guidelines. Materials and methods: A literature review up to March 2004 was carried out using MEDLINE with evaluation of the evidence by an expert panel composed of 23 oncology professionals in clinical medicine, medical oncology, radiation oncology, oncology nursing, statistics, pharmacy, medical policy and decision making, and pharmacology. The experts represented nine oncology professional societies and came from 11 different countries on four continents. Results: Recommendations on antiemetic regimens to prevent emesis induced by high, moderate, low and minimal risk chemotherapy were suggested as well as management of anticipatory emesis. Furthermore, recommendations for refractory emesis, emesis induced by high-dose chemotherapy and radiotherapy and for antiemetics in children receiving chemotherapy were elaborated. Conclusions: Recommendations about antiemetic prophylaxis in patients receiving treatment with chemo- and radiotherapy have been updated by representatives of nine oncological organizations.

KW - 5-HT3-receptor antagonists

KW - Acute emesis

KW - Aprepitant

KW - Delayed emesis

KW - Dexamethasone

KW - Metoclopramide

UR - http://www.scopus.com/inward/record.url?scp=29844438029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29844438029&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdj078

DO - 10.1093/annonc/mdj078

M3 - Article

VL - 17

SP - 20

EP - 28

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -